Therapy Detail

Therapy Name Selinexor
Therapy Description

Selinexor inhibits CRM1, preventing CRM1-mediated nuclear export of tumor suppressor proteins and potentially restoring normal tumor suppressor function (NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Selinexor KPT-330 Selinexor inhibits CRM1, preventing CRM1-mediated nuclear export of tumor suppressor proteins and potentially restoring normal tumor suppressor function (NCI Drug Dictionary).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown thymic carcinoma not applicable Selinexor Preclinical - Cell line xenograft Actionable In a preclinical study, Selinexor (KPT-330) induced cell-cycle arrest and apoptosis and inhibited growth of several thymic epithelial tumor cell lines, including thymoma and thymic carcinoma cell lines, in culture, and inhibited tumor growth in thymic carcinoma cell line xenograft models (PMID: 28819023). 28819023
Unknown unknown glioblastoma multiforme not applicable Selinexor Phase II Actionable In a Phase II trial, Selinexor (KPT-330) treatment resulted in partial response in 11% (3/27) and stable disease in 22% (6/27) of patients with glioblastoma multiforme (J Clin Oncol 34, 2016 (suppl; abstr 2077)). detail...
Unknown unknown prostate cancer not applicable Selinexor Phase II Actionable In a Phase II trial, Selinexor demonstrated preliminary efficacy and poor toxicity profile in patients with abiraterone- and/or enzalutamide-refractory metastatic castration-resistant prostate cancer, resulted in partial response in 25% (2/8) and stable disease in 50% (4/8) of evaluable patients (PMID: 29487219). 29487219
TP53 loss thymoma predicted - resistant Selinexor Preclinical - Cell culture Actionable In a preclinical study, a thymoma cell line with TP53 loss demonstrated primary resistance to Selinexor (KPT-330) in culture, and reconstitution of TP53 expression resulted in increased Selinexor sensitivity (PMID: 28819023). 28819023
Unknown unknown liposarcoma not applicable Selinexor Preclinical - Cell line xenograft Actionable In a preclinical study, Selinexor (KPT-330) decreased Birc5 (Survivin) expression and induced PARP and caspase-3 cleavage, reduced viability of liposarcoma cell lines in culture, and inhibited tumor growth in xenograft models (PMID: 28314790). 28314790
Unknown unknown ovarian cancer not applicable Selinexor Phase I Actionable In a Phase I clinical trial, Selinexor (KPT-330) treatment resulted in inhibition of tumor growth in 3/5 patients with platinum-refractory ovarian cancer, with one patient achieving a partial response and two patients achieving stable disease (PMID: 27649553). 27649553
Unknown unknown Advanced Solid Tumor not applicable Selinexor Phase I Actionable In a Phase I trial, Selinexor (KPT-330) demonstrated safety and preliminary efficacy in patients with advanced solid tumors, resulting in an objective response rate of 4% (7/157; 1 complete response and 6 partial responses) and stable disease in 43% (67/157), with 17% (27/157) of patients demonstrating stable disease for at least 4 months (PMID: 26926685). 26926685
Clinical Trial Phase Therapies Title Recruitment Status
NCT02606461 Phase II Selinexor KCP-330-020 SEAL (Selinexor in Advanced Liposarcoma) (SEAL) Recruiting
NCT02536495 Phase Ib/II Docetaxel Selinexor Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer Withdrawn
NCT02299518 Phase I Etoposide Selinexor Mitoxantrone + Etoposide + Cytarabine Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed
NCT02120222 Phase I Selinexor Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery Recruiting
NCT01607905 Phase I Selinexor Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer Completed
NCT02573363 Phase I Cytarabine Mitoxantrone Selinexor Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia Active, not recruiting
NCT02471911 Phase I Dexamethasone Carboplatin + Etoposide + Ifosfamide + Rituximab Selinexor KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma Recruiting
NCT03193437 Phase II Selinexor Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy Recruiting
NCT02403310 Phase I Daunorubicin + Cytarabine Selinexor A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML Active, not recruiting
NCT02212561 Phase Ib/II Selinexor Cytarabine Cytarabine + Dexamethasone+ Methotrexate Fludarabine Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome Completed
NCT02138786 Phase II Selinexor Study of Selinexor (KPT-330) in Patients With Refractory and/or Relapsed Richter's Transformation (RT) Terminated
NCT02215161 Phase II Selinexor Selinexor (KPT-330) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Prior Therapy With Abiraterone and/or Enzalutamide Terminated
NCT02485535 Phase I Selinexor Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant Active, not recruiting
NCT02146833 Phase II Selinexor Study of Selinexor (KPT-330) in Metastatic Castrate Resistant Prostate Adenocarcinoma Terminated
NCT02402764 Phase II Selinexor Phase 2 Trial of Selinexor (KPT-330) for Metastatic TNBC Active, not recruiting
NCT02250885 Phase II Selinexor KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors Completed
NCT02228525 Phase II Selinexor Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes Active, not recruiting
NCT02227251 Phase II Selinexor Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (SADAL) Active, not recruiting
NCT02091245 Phase I Selinexor Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML Active, not recruiting
NCT02069730 Phase I Selinexor A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes Recruiting
NCT02416908 Phase Ib/II Selinexor Cladribine + Cytarabine + Plerixafor Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia Active, not recruiting
NCT02351505 Phase II Selinexor Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer Terminated
NCT02088541 Phase II Cytarabine Azacitidine Decitabine Selinexor Hydroxyurea Selinexor (KPT-330) in Older Patients With Relapsed AML Completed
NCT03147885 Phase Ib/II Selinexor Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma Recruiting
NCT02419495 Phase I Cyclophosphamide Pemetrexed Eribulin Selinexor Carboplatin Paclitaxel Topotecan Dexamethasone Doxorubicin Selinexor in Combination With Standard Chemotherapy Recruiting
NCT02323880 Phase I Selinexor Study of Selinexor in Pediatric Solid Tumors Recruiting
NCT01986348 Phase II Selinexor Phase 2 Study of Selinexor (KPT-330) in Patients With Recurrent Glioblastoma After Failure of Radiation and Temozolomide Active, not recruiting